Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2021 Mar 2;19(3):254-266.
doi: 10.6004/jnccn.2021.0013.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021

David S Ettinger  1 , Douglas E Wood  2 , Dara L Aisner  3 , Wallace Akerley  4 , Jessica R Bauman  5 , Ankit Bharat  6 , Debora S Bruno  7 , Joe Y Chang  8 , Lucian R Chirieac  9 , Thomas A D'Amico  10 , Thomas J Dilling  11 , Jonathan Dowell  12 , Scott Gettinger  13 , Matthew A Gubens  14 , Aparna Hegde  15 , Mark Hennon  16 , Rudy P Lackner  17 , Michael Lanuti  18 , Ticiana A Leal  19 , Jules Lin  20 , Billy W Loo Jr  21 , Christine M Lovly  22 , Renato G Martins  2 , Erminia Massarelli  23 , Daniel Morgensztern  24 , Thomas Ng  25 , Gregory A Otterson  26 , Sandip P Patel  27 , Gregory J Riely  28 , Steven E Schild  29 , Theresa A Shapiro  1 , Aditi P Singh  30 , James Stevenson  7 , Alda Tam  8 , Jane Yanagawa  31 , Stephen C Yang  1 , Kristina M Gregory  32 , Miranda Hughes  32
Affiliations
Practice Guideline

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021

David S Ettinger et al. J Natl Compr Canc Netw. .

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.

PubMed Disclaimer

Publication types

Substances

LinkOut - more resources